Geron Co. (NASDAQ:GERN) Forecasted to Post FY2028 Earnings of $0.78 Per Share

Geron Co. (NASDAQ:GERN) – Equities research analysts at Wedbush raised their FY2028 earnings per share (EPS) estimates for Geron in a report issued on Thursday, August 8th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will post earnings per share of $0.78 for the year, up from their previous forecast of $0.65. Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.35) per share.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $0.34 million. During the same period last year, the firm posted ($0.09) earnings per share. The business’s revenue for the quarter was up 2941.4% on a year-over-year basis.

Other equities research analysts have also issued reports about the company. Needham & Company LLC restated a “buy” rating and issued a $6.00 price objective on shares of Geron in a research note on Friday. Robert W. Baird downgraded shares of Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price objective for the company. in a report on Tuesday, April 30th. Barclays assumed coverage on shares of Geron in a research report on Monday, June 10th. They set an “overweight” rating and a $9.00 target price on the stock. StockNews.com raised Geron to a “sell” rating in a research report on Monday. Finally, Stifel Nicolaus raised their price target on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, June 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.07.

Geron Stock Performance

GERN stock traded down $0.01 during midday trading on Friday, reaching $4.59. 1,482,451 shares of the company’s stock traded hands, compared to its average volume of 11,390,769. The stock’s 50-day moving average is $4.54 and its 200 day moving average is $3.49. The stock has a market cap of $2.72 billion, a P/E ratio of -13.23 and a beta of 0.48. Geron has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.03.

Institutional Trading of Geron

Several large investors have recently added to or reduced their stakes in GERN. Arizona State Retirement System boosted its position in shares of Geron by 3.1% during the 2nd quarter. Arizona State Retirement System now owns 115,400 shares of the biopharmaceutical company’s stock valued at $489,000 after acquiring an additional 3,465 shares during the last quarter. Victory Capital Management Inc. grew its position in Geron by 135.1% in the second quarter. Victory Capital Management Inc. now owns 138,555 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 79,621 shares during the period. National Bank of Canada FI increased its stake in Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 6,000 shares during the last quarter. TD Asset Management Inc raised its position in Geron by 403.0% in the second quarter. TD Asset Management Inc now owns 1,201,200 shares of the biopharmaceutical company’s stock valued at $5,093,000 after purchasing an additional 962,400 shares during the period. Finally, Rhumbline Advisers grew its holdings in shares of Geron by 16.4% during the 2nd quarter. Rhumbline Advisers now owns 846,768 shares of the biopharmaceutical company’s stock worth $3,590,000 after purchasing an additional 119,550 shares during the period. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Faye Feller sold 287,900 shares of Geron stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $4.63, for a total value of $1,332,977.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Geron news, EVP Faye Feller sold 287,900 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $4.63, for a total value of $1,332,977.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Andrew J. Grethlein sold 674,348 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $4.56, for a total value of $3,075,026.88. The disclosure for this sale can be found here. Insiders sold 1,562,248 shares of company stock worth $6,808,004 in the last three months. 3.10% of the stock is owned by insiders.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.